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Abstract
Background
Some but not all prior studies have shown that women receiving a primaryprophylactic
implantable cardioverter defibrillator (ICD) have a lower risk of death and appropriate
shocks thanmen.
Purpose
To evaluate the effect of gender on the risk of appropriate shock, all-causemortalityand
inappropriate shock in contemporary studies of patients receiving a primaryprophylactic
ICD.
Data Source
PubMed, LIVIVO, Cochrane CENTRAL between 2010 and 2016.
Study Selection
Studies providing at least 1 gender-specific risk estimate for the outcomes of interest.
Data Extraction
Abstracts were screened independently for potentially eligible studies for inclusion. Thereby
each abstract was reviewed by at least two authors.
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Data Synthesis
Out of 680 abstracts retained by our search strategy, 20 studies including 46’657 patients
had gender-specific information on at least one of the relevant endpoints. Mean age across
the individual studies varied between 58 and 69 years. The proportionof women enrolled
ranged from 10% to 30%. Across 6 available studies, women had a significantly lower risk
of first appropriate shock compared with men (pooledmultivariable adjusted hazard ratio
0.62 (95%CI [0.44; 0.88]). Across 14 studies reportingmultivariable adjusted gender-spe-
cific hazard ratio estimates for all-causemortality, women had a lower risk of death than
men (pooled hazard ratio 0.75 (95%CI [0.66; 0.86]). There was no statistically significant
difference for the incidence of first inappropriate shocks (3 studies, pooled hazard ratio 0.99
(95%CI [0.56; 1.73]).
Limitations
Individual patient data were not available for most studies.
Conclusion
In this large contemporarymeta-analysis, women had a significantly lower risk of appropri-
ate shocks and death thanmen, but a similar risk of inappropriate shocks. These data may
help to select patients who benefit from primaryprophylactic ICD implantation.
Introduction
Several landmark studies have shown that the primary prophylactic use of implantable car-
dioverter defibrillators (ICD) among patients with reduced left ventricular ejection fraction
is associated with a significant reduction in all-cause mortality [1–3]. These findings were
rapidly adopted by guidelines and have since then become standard of care in this patient
population.
However, ICDs are costly, can lead to inappropriate ICD therapy and put a heavy burden
on the healthcare system [4, 5], providing an impetus for better risk stratification for primary
prophylactic ICD implantation. Medical treatment for patients with heart failure and reduced
ejection fraction has considerably improved since the publication of the randomized trials for
primary prevention ICD implantation [6]. In addition, the proportion of lower risk patients
with non-ischemic cardiomyopathy among ICD recipients continues to increase. Thus, the
overall benefit from these devicesmay be lower than initially estimated. This may be particu-
larly true for subgroups at lower risk of sudden cardiac death.
Some but not all recent studies have suggested that women may have a lower risk of sudden
cardiac death than men [7–9], suggesting that gender may be an easily determinable factor to
be considered for risk stratification. Two meta-analyses of randomized trials concluded that
women had either no benefit or a smaller benefit than men [10, 11]. Some studies also sug-
gested a higher risk of complications in women, further underscoring the potential importance
of considering gender when balancing risks and benefits of primary prophylactic ICD
implantation.
We therefore performed a systematic review and meta-analysis of contemporary studies to
assess gender related differences in outcomes among patients undergoing primary prophylactic
ICD implantation.
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Methods
Search strategy
The aim of this meta-analysis was to synthesize published results from contemporary studies
regarding the effect of gender on the risk of appropriate shock, all-causemortality and inappro-
priate shock in patients with ICD implanted for primary prevention. Accordingly, we searched
PubMed, LIVIVO and CochraneCENTRAL (date of last search: May 11, 2016) for relevant
studies published from 2010 onward using the following search terms: ("primary prophylaxis"
OR "primary prophylactic" OR "primary prevention") AND ("ICD" OR "defibrillator") AND
("mortality" OR "shock" OR "death" OR "ICD therapy" OR "ICD treatment"). No language
restrictions were applied to the search. We did not consider meeting abstracts or other gray lit-
erature. The year 2010 was chosen as a starting date in order to limit the search to studies that
had enrolled predominantly primary prophylactic ICD patients after the publication of major
landmark trials and corresponding guidelines in the field [1–3]. However, the patient cohorts
might include patients with ICD implantation before 2010. The yield of our search strategy was
checked against a pre-defined list of 19 publications that are related to the topic and that we
had compiled prior to the search. Reference lists of all publications fulfilling the inclusion crite-
ria were also screened to identify additional publications.
Study selection
The abstracts identified by the literature search as described in the previous paragraph were
reviewed independently and each abstract was seen by at least two authors (LB, PM, MZ, BA).
If an abstract was judged as potentially relevant by at least one of the reviewers, the full-text of
the publication was screened 1) for appearance of at least one of the three endpoints of interest
appropriate shock, all-cause death or inappropriate shock, and 2) for reported gender-specific
effects on at least one of the end-points. Further, we required the study population to be limited
to patients with an implanted ICD, with or without cardiac resynchronization therapy (CRT),
and who were enrolled at the time of device implantation, in order to minimize the risk of sur-
vival bias. To focus our results on patients with an ICD implanted for primary prevention, we
considered only papers in which at least 60% of the study population received a primary pro-
phylactic ICD, or in which results for the primary prophylactic subgroup were reported sepa-
rately. In 2 cases we had access to the individual patient data and re-analyzed the data within
the primary prevention subgroup [12, 13]. Papers considering very specific patient popula-
tions, e.g. all patients with CRT-D, all patients older than 80 years, patients after CABG surgery
only or all patients on dialysis, were excluded.
Assessment of study quality
Since this systematic review is based on observational studies only (and does not include ran-
domized controlled trials), we assessed the risk of bias regarding three domains (selection of
participants, measurement of variables and outcomes, control of confounding) specific to
observational studies as previously recommended [14].The study quality was assessed by two
reviewers (BA, CR).
Data extraction
Hazard ratios quantifying the effect of gender were extracted from univariable or multivariable
Cox proportional hazards models, and constituted the effectmeasure of interest. Specifically,
we extracted point estimates, their standard errors (when available) and associated confidence
intervals (CI). The text was screened for consistent reporting of the results, in order to guard
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against possible typographical errors. To the same end, the reported intervals were checked for
symmetry around the point estimate on the log-scale. If inconsistencies were observedor ques-
tions regarding variable definitions arose, we contacted the corresponding authors of the
respective publications and asked for clarification. In cases where individual patient data were
available and the original paper did not report hazard ratios for the primary prophylactic
patients, we obtained the needed hazard ratios by repeating the analysis from the respective
publication using the appropriate data subset.
In addition to hazard ratios, we extracted information on the total number of patients
included, duration of follow up, year of ICD implantation and on a pre-defined list of baseline
characteristics, including gender, age, ischemic cardiomyopathy, NYHA functional class, left
ventricular ejection fraction (LVEF), creatinine concentration and/or glomerular filtration rate,
QRS duration, diabetes mellitus, type of device and primary versus secondary prevention. Data
extracted by one author were independently verified by another author.
Statistical analysis
The extracted hazard ratios were log-transformed and their standard errors, if not available
directly, were calculated from the reported 95% CIs [15]. Random effectsmodels using Man-
del-Paule estimators of the between-study variance were applied to pool the log-transformed
hazard ratios. The 95% CI for the pooled effect estimate was calculated using the Knapp-Har-
tung approach with the suggested ad hoc adjustment [16]. Between-study heterogeneity was
assessed by the CochranQ chi-square test and by the I2measure (as implemented in the R
packagemetafor [17]). The stability of the results was examined by leaving out one study at a
time and re-pooling the remaining hazard ratios. All analyses were done using the R software
(R Foundation for Statistical Computing, Vienna, Austria). A p-value<0.05 was pre-specified
to indicate statistical significance.
Results
Search results
After removing duplicates, the search yielded a list of 680 potentially relevant records. Out of
these, 264 abstracts were identified for full-text screening (Fig 1). The absence of gender-spe-
cific effect estimates on at least one of the endpoints and exclusion of studies on very specific
patient populations narrowed the number of potentially eligible publications to 43. Additional
reasons for exclusions are listed in Fig 1. Results from 1 manuscript [18] were excluded because
of an indirect classification of the prevention type, and because the underlying sample popula-
tion overlapped to a large extent with a more precisely defined primary prevention group from
another study (9).
Thus, 20 papers qualified for our quantitative synthesis [7–9, 12, 13, 19–33], two of them
[26, 28] from the same study population. For the meta-analysis on mortality, the results
reported by Yung et al were considered since their report focusses on the primary prevention
subgroup [28]. For the analyses reporting on appropriate and inappropriate shocks we
included the effect estimates fromMacFadden et al. [26] in our analyses, since standard Cox
proportional hazards analyses were not provided in the former publication [28].
An overviewof the 20 included studies is shown in Table 1 and more detailed characteristics
are presented in Tables 2 and 3. Overall, the included studies provided results on up to 46’657
patients with gender-specific information on at least one of the relevant endpoints. Mean fol-
low-up across the individual studies ranged from 0.78 to 5.4 years. Mean age varied between 58
and 69 years. The proportion of women enrolled ranged from 10% to 30%. The prevalence of
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ischemic cardiomyopathy was between 56% and 100%. All but four studies provided results on
primary prevention patients only.
Assessment for bias
All studies included in the meta-analyses recruited consecutive patients undergoing ICD
implantation, in one case [20] the study population was limited to recipients of dual chamber
ICDs without prior atrial fibrilation, in one case [25] the population of patients with available
NT-proBNP or BNP measurements was complemented by a parallel cohort without thesemea-
surements. All studies provided description of the inclusion/exclusion criteria and matched
our objectives. All studies provided details on the determination of the end-points, however,
only 9 [7, 12, 13, 20–22, 27–29] discussed to some extent measurement of baseline variables. In
all but 5 cases related to all-cause mortality the statistical analyses accounted for confounders,
see also Table 4. We analyzed these 5 studies separately (Fig 2). We did not exclude any of the
identified studies from further analysis after assessment of bias risk.
Appropriate shocks
Effect of gender on the incidence of first appropriate shock was available from 6 studies
(Table 1). Covariates of the multivariable models for the incidence of first appropriate shock
are shown in Table 4. After combining the 6 individual hazard ratios, women had a signifi-
cantly lower risk of receiving an appropriate shock than men, with a pooled risk estimate of
0.62 (95% CI [0.44; 0.88], p = 0.0175) (Fig 3). The between study standard deviation was 0.20
and I2 was 36% with a p-value for heterogeneity of 0.2381. Removing the study by Weeke et al.
eliminated the between study heterogeneity, without significantly influencing the relative risk
Fig 1. Flow diagramof the systematic review. PP = primaryprevention, HR = hazard ratio.
doi:10.1371/journal.pone.0162756.g001
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of appropriate shocks (hazard ratio 0.69, 95% CI [0.52; 0.92], p = 0.0222). Similarly, excluding
any one study from the meta-analysis had no appreciable effect on the overall results, as shown
in S1 Table.
All-causemortality
A gender specific risk estimate for all-causemortality was available in 19 studies. Out of the 19
available hazard ratios, 14 are based on multivariable (covariates listed in Table 4) and 5 on
univariable models.Women had a lower risk of death than men (hazard ratio 0.78, 95% CI
[0.68; 0.89], p = 0.001), as shown in Fig 2. The between study standard deviation was 0.1544
(heterogeneity test p = 0.0436) and I2 was 47%, suggestingmoderate between-study heteroge-
neity. Excluding two small studies [20, 27] reporting extremely wide CIs did not materially
influence the pooled risk estimate (0.79, 95% CI [0.71; 0.87], p = 0.0001), but reduced between
study heterogeneity (between study standard deviation 0.0770, I2 = 20%, heterogeneity test
p = 0.1171). Again, results were stable and not sensitive to the exclusion of any one study from
the meta-analysis, as shown in S1 Table for studies reportingmultivariable adjusted hazard
ratios.
Table 1. Overviewand available endpointsof eligible papers.
Study N patients Implantation period PP [%] Appropriate shock All-causemortality Inappropriate shock
van der Heijden et al 1946 1996–2012 100 yes yes yes
Seegers et al* 632 2000–2010 100 yes yes —
Weeke et al 1609 2007–2011 100 yes yes yes
Wijers et al* 553 2006–2011 100 yes yes —
Yung et al* 3939 2007–2010 100 —& yes —
Gatzoulis et al† 422/495 1992–2010 78.4/76.3 yes yes —
MacFadden et al 5213 2007–2010 70 yes yes# yes
Bilchick et al 17991 2005–2006 100 — yes —
Gigli et al 193 2003–2010 100 —- yes —-
Hage et al* 409 2002–2007 100 — yes —
Masoudi et al 2954 2006–2010 100 — yes —
Providência et al 5539 2002–2012 100 — yes —
Rodríguez-Mañero et al 1174 2008–2011 100 — yes —
Smith et al 427 2004–2009 100 — yes —
Amit et al 1518 2010–2013 70§ — yes —
Campbell et al 197 2003–2009 100 — yes —
Demirel et al 94 2004–2010 100 — yes —
Kraaier et al 861 2002–2008 100 — yes —
Levine et al 783 2003–2012 100 — yes —
Stabile et al 130 2002–2003 >70 — yes —
PP = Primary prevention
* Primaryprevention subgroup
† Subgroup of patients with LVEF< = 35%/all patients
§ Indirect estimate based on the 74% of PP in the baseline cohort (3543 patients) and the claim of no significant baseline differences between patients with
and without follow-up
# Not included in the meta-analysis, given a large overlap with Yung et al
& Appropriate shock considered, but hazard ratio from a Cox proportional hazardsmodel not provided.
doi:10.1371/journal.pone.0162756.t001
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Inappropriateshock
Effect of gender on the risk of first inappropriate shock was available in 3 studies. Gender had
no apparent effect on the occurrence of inappropriate shocks, with a pooled hazard ratio of
0.99 (95% CI [0.56–1.73], p = 0.9276) and no evidence for heterogeneity (I2 = 0, heterogeneity
test p = 0.47), as shown in Fig 4. Excluding any one study from the meta-analysis had no appre-
ciable effect on the overall results (see S1 Table).
Table 2. Baseline characteristics of the selected studies.
Baseline
characteristic
van der
Heijden
et al
Seegers
et al (PP
only)
Weeke et al Wijers et al
(PP only)
Yung et al
(PP only)
Gatzoulis et al
(LVEF35%)
MacFadden
et al
Bilchick
et al.
Gigli
et al.
Hage
et al.
(PP
only)
n 1946 632 1609 553 3939 422 5213 17991 193 409
Follow-up [y] 3.3 (1.4–
5.4)
4.2±2.1 1.9±1.3 2.4±1.57 1.8 (1.0–
2.8)
3.3±2.92* 0.78* (mean) up to 5
years
4.2*
(mean)
4.2±2**
Male 78.5% 82% 84.2%* 72% 80.2%* 90% 78.8%* 77.5%* 84% 70.2%*
Age [y] 65±15 65.5±12 M:67.5
(60.7–73.2)
F:69.0
(61.0–74.6)
63.3±11.4 65.2
±10.75*
65.6±10.2 n.g.§ <74: 61.2%
*75:
38.8%*
64.4
±10
58
±14.2*
ICM 66% 67.2% 100% 61.8% 70.4%* 69.4% n.g. n.g. 62% n.g.
NYHA 2.6±0.6 n.g.
I 18.3% 14.7% 6.2%* 6.9% 23.1%* n.g.§ 8.8% 14.7%*
II 34.6% 24.7% 50.5%* 26.6% 40.7%* n.g.§ 51.0% 37.2%*
III- IV 44.8%* 59% 38.3%* 42% 36.2%* n.g.§ 40.2% (III) 43.7%*
unknown 2.3% 1.6% 5%* 24.6% 0% 0% 4.4%*
LVEF [%] 29±11.7 27±8.6ǂ 25(20–30)* 23.5±6.31 20: 21.1%
* 20–30:
55.5%*
31: 18.4%
* NA: 5%*
26.9±15.5 n.g.§ NA:
1039 of 5213
20: 31.6% 26±6 26±13*
Creatinine (C)/
eGFR[mL/min/
1.73m2]
C: 78.7
±36.4ml/
min
eGFR:
65.9
±23.3ǂ
n.g. eGFR: 63.7
±26.7 C:114.2
±61.7 μmol/L
C:111.2
±62.9*
μmol/L
n.g. n.g.§ n.g. n.g. eGFR:
70±23
QRS [ms] 132±35.9 129±37ǂ SC: 100(90–
115) DC:
100(90–120)
CRT-D: 150
(130–168)
135.6±32.8 134.0
±35.53*
n.g. n.g.§ <120:
59.0% 120–
149: 22.2%
150:
18.8%
n.g. 133±34
Diabetes 23% 27.2% n.g. n.g. 37%* n.g. n.g.§ 33.6% n.g. 33.5%
Primary prev. 100% 100% 100% 100% 100% 78.4%* 70%** 100% 100% 100%
Type of device n.g. n.g.§ n.g. n.g.§
SC 4% 29.1% 46.2% 45.9% 43.5%* 72.5%*
DC 38% 25.6% 16.8% 7.1% 23.5%* 27.5%*
CRT-D 58% 45.3% 37.0% 47.0% 33%* 0%
The values are given as percentages, mean±SDor median (IQR). PP = primaryprevention, M = male, F = female, SD = standard deviation,
IQR = interquartile range, n.g. = not given, SC = Single chamber, DC = Dual chamber, CRT-D: Cardiac resynchronization therapy-defibrillator.
NA = unknown, y = year.
* calculated
** calculated from 5450 pts undergoing ICD implantation (237 later excluded due to the lack of follow-up)
§ numbers given only for a larger group of pts referred to ICD implantation
ǂ calculated from non-missing values
doi:10.1371/journal.pone.0162756.t002
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Discussion
In this meta-analysis of contemporary studies among patients receiving a primary prophylactic
ICD because of a depressed left ventricular ejection fraction, we found that women have a
lower incidence of a first appropriate shock and death than men, but a similar risk of receiving
inappropriate shocks. These results provide important insights on the risk-benefit ratio in spe-
cific subpopulations eligible for primary prophylactic ICD implantation.
Some of the included studies included a significant proportion of patients with ICD implan-
tation for secondary prophylaxis. To investigate whether this might potentially bias any
Table 3. Baseline characteristics of the selected studies.
Baseline
characteristic
Masoudi et al Providência
et al
Rodríguez-
Mañero et al
Smith et al Amit
et al
Campbell et al Demirel
et al
Kraaier
et al
Levine
et al
Stabile
et al
n 2954 5539 1174 427 1518 197 94 861 783 130
Follow-up [y] 2.4(1.3–3.8) 2.7 (med) 3.2±1.8 2.6(1.25–
3.75)*
0.88
(med)
2.8 (med) 5.4(4.5–
6.6)
up to 1 y 3.6±3.1 5.25±1
Male 74% 84.9%* 81.4%* 79% 83%* 85.8% 86.2% 78.7% 78.4% 77%˧
Age [y] 69(60–75) 62.5±11.2 62.7±11.1 58±14 n.g.& 66.7±9.6 65±10.7 62.7
±10.2
n.g.# 66±9 ˧
ICM 62.2% 59.6%* 56%* 68% n.g.& 100% 100% 67.1%*ǂ n.g.# 56% ˧
NYHA n.g.& n.g.#
I 8.7%* n.g. n.g. 36.2%* 3% ˧
II 61.2%(I+II) 33.6%* n.g. 81.3% (I-II) n.g. 42.6%* 67.6%*
(I-II)
23% ˧
III- IV 38.6% 40.3%* 38.8%* 18% 64.5%* 19.1% *
(III)
32.3% * 74% ˧
unknown 0.2% 17.4%* n.g. 0.7% 11.7%* 2.1%* 0.1%* 0% ˧
LVEF [%] 30: 85.4%
31–35:14.6%
26.7±7.2 26.2±7.6 27±9 n.g.& 25.8(20.0–30.0)ǂ 31.9±9.3 24.3±8.7ǂ n.g.# 30±9 ˧
Creatinine (C)/
eGFR[mL/min/
1.73m2]
C: 1.4±0.9
mg/dL eGFR:
61.5±22.5
eGFR: <60:
23%*
C: 1.18±0.6
mg/dL
C: 97
±41 μmol/L
eGFR: 78
±26
n.g.& eGFR:90:
8.1%, 60–89:
35.5%, 30–59:
49.7%,<30: 6.6%
n.g. eGFR:
74.4
±63.3ǂ
n.g.# n.g.
QRS [ms] >120: 49.1% <120: 21.4%* 127.7±32.2 116±26 n.g.& n.g. n.g. 127±33ǂ n.g.# 138±34
˧
Diabetes 42.2% n.g. 33.0% 21% n.g.& 32% ǂ 22.3%* ǂ 18.2%*ǂ n.g.# 20% ˧
Primary prev. 100% 100% 100% 100% 70%□ 100% 100% 100% 100% 74% ˧
Type of device n.g.& n.g. n.g. n.g.#
SC 32.3% 22.7% 38.9% 74% 0% n.g.
DC 36.0% 23.1% 18.9% 26% 100% n.g.
CRT-D 31.7% 53.3% 42.2%* 0% 0% 65% ˧
The values are given as percentages, mean±SDor median (IQR).Med = median.M = male, F = female, SD = standard deviation, IQR = interquartilerange,
n.g. = not given, SC = Single chamber, DC = Dual chamber, CRT-D: Cardiac resynchronization therapy-defibrillator.
* calculated
** in a larger cohort including secondary prevention patients
§ 42.5% pts had ICD with biventricular pacing device
& not given for the subgroup of patients with follow-up
□ see note under Table 1
ǂmissing values excluded
# not given for the larger cohort underlying all-causemortality results
˧ in a larger cohort of 139 patients (for 9 missing information on survival status)
doi:10.1371/journal.pone.0162756.t003
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conclusions for primary prophylactic ICD implantation we performed sensitivity analyses
including only studies completely focused on primary prevention. The combined effects were
very similar to the findings reported here providing reassurance in the approach taken.
The proportion of participants with ischemic cardiomyopathy in the included cohorts was
relatively high, a group of patients with a higher mortality risk than those with non-ischemic
cardiomyopathy. In the MADIT-II study, where only patients after a myocardial infarction
were enrolled, mortality rate at 2 years was approximately 15% in the intervention group [2].
SCD-Heft enrolled a mixed population of ischemic and non-ischemic cardiomyopathies
and found a risk of death at 2 years in the intervention group of approximately 11–12% [1].
Estimated 2-year mortality rates from the cohorts included in this analysis are shown in the
Table 4. List of covariates for which the reportedhazard ratioswere adjusted.
van der Heijden
et al
- AS, M: age, aetiology of heart failure, device type, LVEF, NYHA class, history of
atrial fibrillation/flutter, creatinine clearance, usage of β-blockers
- IAS: atrial fibrillation/flutter
Seegers et al - AS: age, Amiodarone;
-M: age, eGFR, diuretics, peripheral arterialdisease
Weeke et al - AS, IAS: age, QRS duration, LVEF, type of device (time dependent), history of
percutaneous intervention, history of CABG, implantation year, atrioventricular
conduction disease, device upgrade
-M: as for AS, plus therapy during follow up (appropriate/inappropriate shock,
appropriate/inappropriateATP)
Wijers et al - AS: LVEF, ischemic cardiomyopathy
-M: LVEF, QRS duration, GFR
Yung et al -M: age, NYHA class, syncope, peripheral vascular disease, GFR, left atrial size,
prescribedACE inhibitors or ARB, prescribed loop diuretics
Gatzoulis et al - AS: age, ICM, prevention type
-M: age, ischemic cardiomyopathy, LVEF< = 35%, NYHA, type of prevention
MacFadden et al - AS, IAS: age, QRS duration, creatinine, hemoglobin, systolic and diastolic blood
pressure (each squared), NYHA, ventricular tachycardia or fibrillationor
nonsustained ventricular tachycardia, myocardial infarction, previous percutaneous
coronary intervention or CABG, heart failure, family history of SCD, atrial fibrillation,
valvular heart disease, syncope, dyslipidemia, diabetesmellitus, hypertension,
previous stroke or transient ischemic attack, peripheral vascular disease, COPD,
LVEF, device type
Bilchick et al -M: age, race, QRS duration, bundle branch block, atrial fibrillation, LVEF, NYHA,
duration of heart failure, diabetesmellitus, COPD, chronic kidney disease, prior
myocardial infarction, prior CABG, systolic blood pressure, diastolic blood pressure,
heart rate, digoxin, beta-blockers, ACE inhibitors, diuretic agents, Amiodarone,
Warfarin, breast cancer, colon cancer, prostate cancer, depression
Gigli et al -M: age, LVEF, type of device, ischemic cardiomyopathy
Hage et al -M: age, hypertension, atrial fibrillation, myocardial infarction, LVEF, left bundle
branch block, biventricular pacing, Amiodarone, other antiarrhythmics, β-blockers,
chronic kidney disease
Masoudi et al -M: LVEF, ischemic cardiomyopathy, NYHA, blood urea nitrogen, atrial fibrillation,
diabetes, hypertension, chronic lung disease, hemoglobin, QRS, device type, ACE/
ARB therapy, β-blockers
Providência et al. -M:NYHA, atrial fibrillation, ischemic cardiomyopathy, QRS, CRT-D, β-blockers,
Amiodarone, spironolactone, calcium channel blockers, antiplatelet agents, vitamin
K antagonists
Rodríguez-Mañero
et al.
-M: LVEF, age, creatinine, COPD, digoxin therapy
Smith et al -M: age, NYHA, diuretic use, ACE inhibitor use, renal failure
Amit et al -M: age, device type, LVEF, prevention type, diabetes, β-blockers, renal function
AS = appropriateshock, M = all-cause mortality, IAS = inappropriate shock.
doi:10.1371/journal.pone.0162756.t004
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S2 Table. These rates obtained from contemporary cohort studies are comparable to those in
ScD-Heft or even slightly lower, potentially showing the improvements of medical treatment
among patients with heart failure and reduced ejection fraction over the last 15 years [34, 35].
Assuming a similar relative benefit of primary prophylactic ICD implantation despite lower
Fig 2. Extractedhazard ratios for female gender regarding risk of appropriate shockswith 95% confidence
intervals as reported in the respective publications. ‘PP’ indicates that the results were re-analyzed for primary
prevention patients only. The pooled estimate is reportedwith a Knapp-Hartung adjusted 95% confidence interval.
The dotted vertical line denotes a hazard ratio of 1, which corresponds to no difference in the risk betweenmales and
females.
doi:10.1371/journal.pone.0162756.g002
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mortality rates, the absolute benefit of the device decreases in the context of an improved sur-
vival in this patient population.
These are important considerations, as ICDs are costly and their implantation is associated
with the occurrence of several important complications such as inappropriate shocks, infec-
tions and lead malfunction. In an earlier study, the rate of major complications in the first year
after ICD implantation was 13.9 per 100 person-years among women and 7.4 per 100 person-
years among men, with an adjusted odds ratio of 1.91 (1.48–2.47; p<0.001) [26]. In the current
meta-analysis we showed that women had a 22% lower risk of death and a 38% lower risk of
appropriate shocks compared with men but a similar risk of inappropriate shocks.
Thus, the available evidence suggests that the risk-benefit ratio might be less favorable in
women and the number needed to save one life higher. While our findings do certainly not
mean that primary prophylactic ICD therapy should be withheld in women, they do suggest
that in the context of diminishing absolute benefits and growing costs in most health care sys-
tems that improved risk stratification tools for primary prophylactic ICD implantation in
patients with heart failure are urgently needed and are likely to include gender as a prognostic
factor. Prior meta-analyses of randomized trials have shown that women have a similar risk of
death but a lower risk of appropriate shocks compared with men [11], suggesting that at least
the lower risk of appropriate shocks found in our study is not entirely due to confounding.
Taken together, improved risk stratification is needed to allocate primary prophylactic ICD
treatment, and gender may be one of many possible risk factors, such as life expectancy,
chronic kidney disease, atrial fibrillation or chronic obstructive pulmonary disease [19, 36].
Strengths of this comprehensive meta-analysis include the large sample size and the focus
on contemporary patients treated after the publication of the landmark studies in the field.
Fig 3. Extractedhazard ratios for female gender regarding risk of all-causemortality with 95% confidence
intervals as reported in the respective publications. ‘PP’ indicates that the results were re-analyzed for primary
prevention patients only. The pooled estimate is reportedwith a Knapp-Hartung adjusted 95% confidence interval.
The dotted vertical line denotes a hazard ratio of 1, which corresponds to no difference in the risk betweenmales and
females.
doi:10.1371/journal.pone.0162756.g003
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The current analysis should also be interpreted in the context of its limitations. First, as we
intentionally focused on recent publications, the included studies were all observational, and
the causality of the observed associations is uncertain. Second, this is a study level meta-anal-
ysis, as individual patient data were not available for most studies. Finally, it is important to
note that our results do not apply to patients qualifying for secondary prophylactic ICD
treatment.
In conclusion, in contemporary cohorts of patients receiving a primary prophylactic ICD,
women have lower risks of death and appropriate shocks than men, but a similar risk of inap-
propriate shocks. These findings were observed in studies with a relatively low 2-year mortality.
Our data suggest that further studies are warranted to validate the described gender-related dif-
ferences and to defined improved risk stratification tools for primary prophylactic ICD implan-
tation in patients with heart failure.
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